data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
ChemoCentryx
(NASDAQ:CCXI)
$50.86
0.05[0.10%]
At close: Aug 16
$50.86
After Hours: 4:04PM EDT
Day High/Low50.8 - 51.24
52 Week High/Low14.95 - 51.06
Open / Close50.82 / 50.86
Float / Outstanding- / 71.4M
Vol / Avg.2.6M / 2.1M
Mkt Cap3.6B
P/E-
50d Avg. Price28.61
Div / Yield-
Payout Ratio-
EPS-0.44
Total Float57.6M

ChemoCentryx (NASDAQ:CCXI), Quotes and News Summary

ChemoCentryx (NASDAQ: CCXI)

Day High/Low50.8 - 51.24
52 Week High/Low14.95 - 51.06
Open / Close50.82 / 50.86
Float / Outstanding- / 71.4M
Vol / Avg.2.6M / 2.1M
Mkt Cap3.6B
P/E-
50d Avg. Price28.61
Div / Yield-
Payout Ratio-
EPS-0.44
Total Float57.6M
Sector: Health Care.Industry: Biotechnology
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Read More

Earnings

see more
Q3 2022Est.ActualSurprise
EPS
(EXPECTED)2022-11-08
REV
Q2 2022Est.ActualSurprise
EPS-0.490-0.440 0.0500
REV13.070M11.763M-1.307M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

ChemoCentryx Questions & Answers

Q
How do I buy ChemoCentryx (CCXI) stock?
A

You can purchase shares of ChemoCentryx (NASDAQ: CCXI) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are ChemoCentryx's (CCXI) competitors?
Q
What is the target price for ChemoCentryx (CCXI) stock?
A

The latest price target for ChemoCentryx (NASDAQ: CCXI) was reported by Stifel on Wednesday, August 10, 2022. The analyst firm set a price target for 52.00 expecting CCXI to rise to within 12 months (a possible 2.24% upside). 12 analyst firms have reported ratings in the last year.

Q
Current Stock Price for ChemoCentryx (CCXI)?
A

The stock price for ChemoCentryx (NASDAQ: CCXI) is $50.86 last updated August 16, 2022, 8:00 PM UTC.

Q
Does ChemoCentryx (CCXI) pay a dividend?
A

There are no upcoming dividends for ChemoCentryx.

Q
When is ChemoCentryx (NASDAQ:CCXI) reporting earnings?
A

ChemoCentryx’s Q3 earnings are confirmed for Tuesday, November 8, 2022.

Q
Is ChemoCentryx (CCXI) going to split?
A

There is no upcoming split for ChemoCentryx.

Q
What sector and industry does ChemoCentryx (CCXI) operate in?
A

ChemoCentryx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.